|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
MARCH 19, 2007
How Hythiam Will Tackle Drink And Drugs  With alcohol and drug abuse continuing to be a nationwide scourge, some investors are hopeful that Hythiam's PROMETA may help curb the problem. Hythiam (HYTM
) licenses PROMETA to treatment centers, managed-care providers, and government agencies. Using a combination of nutritional supplements and Food & Drug Administration-approved oral and intravenous medications, PROMETA can reduce cravings and promote abstinence, say analysts. Although still controversial, "early results from open-label studies and drug court trials have been overwhelmingly successful," says Ryan Daniels of William Blair, which has done banking for Hythiam. Daniels, who rates Hythiam a buy, says licensees and clinical researchers express "strong satisfaction with, and belief in, the protocol." Donald Hooker of UBS (UBS
) (it did banking for Hythiam) says his buy rating, with a 12-month target of 15, is centered on "the clinical efficacy of PROMETA." Its stock doubled, from 4.77 in July to 10 on Jan. 12, before easing to 7.86 since the Feb. 27 market meltdown. "We are encouraged by the increasing evidence that PROMETA can change the paradigm of substance-abuse treatment," says Jack Silver, president of Siar Capital, which owns shares.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2007, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version